Towards an Epitope-Based Human Vaccine for Influenza

The conventional, currently available vaccines against influenza virus, though quite successful, suffer from a few shortcomings; one major limitation is their restriction to the specific strains that are included in the vaccine. We review herewith some of the more recently developed influenza vaccines and further describe our own results on the design of epitope-based vaccine for human use. In this vaccine, a combination of B- and T-cell epitopes are individually expressed within an immunogenic molecule – salmonella flagellin - and the resultant recombinant flagella serve both as a carrier and as an adjuvant. The mixture of recombinant flagella expressing the appropriate epitopes was administered to young and aged mice as well as to human/mouse chimera model in which human PBMC are functioning within the mice body. Intranasal immunization in all these animal models led to effective protection against challenge infection with different strains of influenza virus.

[1]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[2]  N. Bardiya,et al.  Influenza vaccines: recent advances in production technologies , 2005, Applied Microbiology and Biotechnology.

[3]  M. Zambon,et al.  Confronting the avian influenza threat: vaccine development for a potential pandemic , 2004, The Lancet Infectious Diseases.

[4]  R. Belshe.  Current status of live attenuated influenza virus vaccine in the US. , 2004, Virus research.

[5]  P. Bourée.  Immunity and immunization in elderly. , 2003, Pathologie-biologie.

[6]  R. Webster,et al.  Are We Ready for Pandemic Influenza? , 2003, Science.

[7]  T. Ben-Yedidia,et al.  Old and new vaccine approaches. , 2003, International immunopharmacology.

[8]  K. Mittenbühler,et al.  Lipopeptides: adjuvanticity in conventional and genetic immunization. , 2003, FEMS immunology and medical microbiology.

[9]  Harry Greenberg,et al.  Novel generations of influenza vaccines. , 2003, Vaccine.

[10]  D. Geier,et al.  Influenza vaccination and Guillain Barre syndrome. , 2003, Clinical immunology.

[11]  S. Halperin,et al.  Mucosal Immunization with a Genetically Engineered Pertussis Toxin S1 Fragment-Cholera Toxin Subunit B Chimeric Protein , 2003, Infection and Immunity.

[12]  H. Heine,et al.  Toll-Like Receptors and Their Function in Innate and Adaptive Immunity , 2003, International Archives of Allergy and Immunology.

[13]  T. Ross,et al.  Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. , 2003, Vaccine.

[14]  Chin-fen Yang,et al.  Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. , 2003, Virology.

[15]  R. Mischler,et al.  Inflexal V a trivalent virosome subunit influenza vaccine: production. , 2002, Vaccine.

[16]  M. Murtaugh,et al.  Inflammatory cytokines and antigen presenting cell activation. , 2002, Veterinary immunology and immunopathology.

[17]  K. Subbarao,et al.  DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. , 2002, Emerging infectious diseases.

[18]  M. Hernández-González,et al.  New approaches to improve a peptide vaccine against porcine Taenia solium cysticercosis. , 2002, Archives of medical research.

[19]  A. Purcell,et al.  The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. , 2002, Current drug targets.

[20]  A. Osterhaus,et al.  Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. , 2002, Vaccine.

[21]  J. Wood.  Developing vaccines against pandemic influenza. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[22]  D. Jackson,et al.  Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. , 2001, Mini reviews in medicinal chemistry.

[23]  S. Nishimura,et al.  Characterization of a human H9N2 influenza virus isolated in Hong Kong. , 2001, Vaccine.

[24]  R. Jennings,et al.  Influenza vaccination in old age. , 2001, Age and ageing.

[25]  K. Meyer.  The role of immunity in susceptibility to respiratory infection in the aging lung , 2001, Respiration Physiology.

[26]  K. Murthy,et al.  Flagellin, a Novel Mediator of Salmonella-Induced Epithelial Activation and Systemic Inflammation: IκBα Degradation, Induction of Nitric Oxide Synthase, Induction of Proinflammatory Mediators, and Cardiovascular Dysfunction1 , 2001, The Journal of Immunology.

[27]  B. F. Hall,et al.  Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. , 2000, The Journal of infectious diseases.

[28]  C. Frömmel,et al.  Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. , 2000, Virology.

[29]  D. Schechtman,et al.  Intranasal Administration of Synthetic Recombinant Peptide-Based Vaccine Protects Mice from Infection by Schistosoma mansoni , 1999, Infection and Immunity.

[30]  T. Ben-Yedidia,et al.  Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. , 1999, International immunology.

[31]  J. Ulmer,et al.  Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. , 1999, Journal of immunology.

[32]  Galun,et al.  Antigen‐specific B and T cells in human/mouse radiation chimera following immunization in vivo , 1999, Immunology.

[33]  A. Globerson,et al.  Efficacy of anti-influenza peptide vaccine in aged mice , 1998, Mechanisms of Ageing and Development.

[34]  A. McMichael,et al.  Differential processing of influenza nucleoprotein in human and mouse cells , 1998, European journal of immunology.

[35]  N. Cox,et al.  Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. , 1998, Science.

[36]  A. Canaan,et al.  Generation of primary antigen-specific human cytotoxic T lymphocytes in human/mouse radiation chimera. , 1996, Blood.

[37]  E. Galun,et al.  Human/mouse radiation chimera are capable of mounting a human primary humoral response. , 1995, Blood.

[38]  T. Sasazuki,et al.  Functional interaction between human histocompatibility leukocyte antigen (HLA) class II and mouse CD4 molecule in antigen recognition by T cells in HLA-DR and DQ transgenic mice , 1994, The Journal of experimental medicine.

[39]  M. Steinitz,et al.  Engraftment of human peripheral blood lymphocytes in normal strains of mice. , 1994, Blood.

[40]  M. Katagiri,et al.  [Analysis of binding capacities between HLA class II molecules and synthetic peptides HA307-319]. , 1993, [Hokkaido igaku zasshi] The Hokkaido journal of medical science.

[41]  A. Suhrbier,et al.  Prediction of an HLA B8-restricted influenza epitope by motif. , 1993, Immunology.

[42]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[43]  J. Coligan,et al.  The peptide binding specificity of HLA class I molecules is largely allele-specific and non-overlapping. , 1992, Molecular immunology.

[44]  J. Coligan,et al.  Overlapping epitopes that are recognized by CD8+ HLA class I-restricted and CD4+ class II-restricted cytotoxic T lymphocytes are contained within an influenza nucleoprotein peptide. , 1992, Journal of immunology.

[45]  C Oseroff,et al.  On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. , 1991, Journal of immunology.

[46]  R. Lechler,et al.  Contribution of T-cell receptor-contacting and peptide-binding residues of the class II molecule HLA-DR4 Dw10 to serologic and antigen-specific T-cell recognition. , 1991, Human immunology.

[47]  P. Parham,et al.  Peptide binding to empty HLA-B27 molecules of viable human cells , 1991, Nature.

[48]  A Sette,et al.  Truncation analysis of several DR binding epitopes. , 1991, Journal of immunology.

[49]  R. Anderson,et al.  HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  F. Liew,et al.  Identification and characterization of T helper epitopes in the nucleoprotein of influenza A virus. , 1989, Journal of immunology.

[51]  J. Trowsdale,et al.  Reversal of HLA restriction by a point mutation in an antigenic peptide. , 1989, International immunology.

[52]  J. Y. Wu,et al.  Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[53]  C. Jacob,et al.  Immune response to cholera toxin epitope inserted in Salmonella flagellin. , 1989, Science.

[54]  A. McMichael,et al.  Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2 , 1987, Nature.

[55]  C. Warlow,et al.  INFLUENZA VACCINATION AND GUILLAIN-BARRÉ SYNDROME , 1984, The Lancet.

[56]  I. Wilson,et al.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution , 1981, Nature.

[57]  G. Air,et al.  Amino acid sequence changes in the haemagglutinin of A/Hong Kong (H3N2) influenza virus during the period 1968–77 , 1980, Nature.

[58]  Harry Jerome.  Production , 1929, American Journal of Sociology.

[59]  Saralees Nadarajah,et al.  Letter to the editor , 2007, Int. Trans. Oper. Res..

[60]  J. Rothbard,et al.  Class I MHC molecules rather than other mouse genes dictate influenza epitope recognition by cytotoxic T cells , 2004, Immunogenetics.

[61]  W. P. Glezen,et al.  Control of influenza. , 2004, Texas Heart Institute journal.

[62]  Ying-hua Chen,et al.  Epitope-vaccine strategy against HIV-1: today and tomorrow. , 2003, Immunobiology.

[63]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[64]  J. Skehel,et al.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.

[65]  R. Arnon,et al.  Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. , 1996, Vaccine.

[66]  R. Arnon,et al.  Synthetic recombinant vaccine induces anti-influenza long-term immunity and cross-strain protection. , 1996, Advances in experimental medicine and biology.

[67]  R. Kennedy,et al.  Expression and immunogenicity of an 18-residue epitope of HIV1 gp41 inserted in the flagellar protein of a Salmonella live vaccine. , 1995, Research in microbiology.

[68]  C Leclerc,et al.  Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. , 1995, Vaccine.

[69]  B. Stocker,et al.  Immune responses to epitopes inserted in Salmonella flagellin. , 1994, International reviews of immunology.

[70]  R. Arnon,et al.  Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice. , 1992, Vaccine.

[71]  D. Mosier.  Adoptive transfer of human lymphoid cells to severely immunodeficient mice: models for normal human immune function, autoimmunity, lymphomagenesis, and AIDS. , 1991, Advances in immunology.

[72]  M. Sela,et al.  Priming immune response to cholera toxin induced by synthetic peptides , 1986, European journal of immunology.

[73]  M. Shapira,et al.  A synthetic vaccine against influenza with built-in adjuvanticity. , 1985, International journal of immunopharmacology.

[74]  M. Shapira,et al.  Anti-influenza response achieved by immunization with a synthetic conjugate. , 1982, Proceedings of the National Academy of Sciences of the United States of America.